Inflammatory malignant fibrous histiocytoma (IMFH) associated with leukemoid reaction (LR)/leukocytosis is a rare entity. In this paper, we search PubMed for all known cases of IMFH associated with LR/leukocytosis in an attempt to draw conclusions about this variant's response to treatments and its pathophysiology. Medline electronic database was searched using key words such as malignant fibrous histiocytoma, leukemoid reaction, and leukocytosis. A total of 16 patients were found, twelve males (75%) and 4 female (25%), with a mean age of 62.6 years, ranging from 47 to 77. The mean survival was 770 days, ranging from 14 to 6570 days. Four patients were alive at last follow-up: 6570 days, 1095 days, 335 days, and 180 days, respectively. Of the 12 patients that expired, death occurred approximately 92 days after the onset of LR or leukocytosis, ranging from 3 to 334 days. We conclude that IMFH associated with LR/leukocytosis does not completely respond to chemoradiation. Overproduction of growth factors and cytokines by IMFH cells and their interactions with the inflammatory infiltrate seem to promote immunological effector cell's dysfunction and substantiate the development and growth of this neoplasm. A clear understanding of these molecular pathways is crucial in order to identify targets for potential therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477745 | PMC |
http://dx.doi.org/10.5402/2012/946019 | DOI Listing |
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing210011, China.
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou450052, China.
To investigate the clinicopathological and molecular genetic characteristics of intracranial mesenchymal tumors with FET::CREB fusion transcript. The clinical and imaging data of 6 cases of intracranial mesenchymal tumors with FET::CREB fusion from December 2018 to December 2023 were collected at the First Affiliated Hospital of Zhengzhou University. Their histological features, immunophenotype and molecular characteristics were analyzed.
View Article and Find Full Text PDFRadiol Case Rep
March 2025
Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 601 N Caroline St, Baltimore, MD, 21287, USA.
Solitary fibrous tumors are rare and typically benign fibroblastic neoplasms with a mean age of onset ranging from 60 to 70 years. Solitary fibrous tumors may arise anywhere within the body, however the pleura is the most common site of origin for these tumors, with approximately 30% of tumors arising from the pleura. In this report we highlight the case of a 62-year-old woman who presented with gradually progressive left sided chest pain that was eventually diagnosed as a pleural SFT.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Department of Surgery, Sinai Grace Hospital, Detroit Medical Center, Detroit, Michigan, USA.
Solitary fibrous tumours (SFTs) are rare soft tissue masses that are often clinically silent until they cause mass effect. A paraneoplastic syndrome manifesting as persistent hypoglycaemia, termed Doege-Potter syndrome (DPS), can be associated with these lesions. Surgical treatment is recommended for the management of these tumours.
View Article and Find Full Text PDFJ Cutan Pathol
January 2025
Division of Dermatology, The University of Texas at Austin, Dell Medical School, Austin, Texas, USA.
Pemetrexed is a chemotherapeutic, antimetabolite agent that has been used in oncology to treat diseases such as metastatic non-small cell lung cancer and unresectable malignant pleural mesothelioma. Pemetrexed use may result in pseudocellulitis, which presents as poorly demarcated patches or plaques with erythema, edema, warmth, and tenderness. These lesions can present unilaterally or bilaterally on the lower extremities.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!